Company Description
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Dr. Sekar Kathiresan M.D. |
Contact Details
Address: 201 Brookline Avenue, Suite 601 Boston, Massachusetts 02215 United States | |
| Phone | (978) 501-3026 |
| Website | vervetx.com |
Stock Details
| Ticker Symbol | VERV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001840574 |
| CUSIP Number | 92539P101 |
| ISIN Number | US92539P1012 |
| Employer ID | 82-4800132 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Burt A. Adelman M.D. | Co-Founder and Independent Chairman of the Board |
| Dr. Sekar Kathiresan M.D. | Co-Founder, Chief Executive Officer and Director |
| Andrew D. Ashe J.D. | President, Chief Operating Officer and General Counsel |
| Dr. Andrew Bellinger M.D., Ph.D. | Chief Scientific Officer |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Issi Rozen M.B.A. | Co-Founder and Strategic Advisor |
| Allison Dorval | Chief Financial Officer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |